{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T23:53:36Z","timestamp":1786751616834,"version":"build-2736575974"},"reference-count":22,"publisher":"Harborside Press, LLC","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:p>Infant-type hemispheric glioma (IHG) is a rare pediatric brain tumor with variable response to chemotherapy and radiotherapy. Molecular insights into IHG can be useful in identifying potentially active targeted therapy. A male fetus was found to have congenital hydrocephalus at the gestational age of 37 weeks. Fetal MRI showed a 2.6\u2009\u00d7\u20092.0-cm tumor located at the frontal horn of the left lateral ventricle, involving the left basal nuclei and thalamus. Tumor biopsy at the age of 2 days revealed an IHG consisting of spindle tumor cells with strong expression of GFAP and ALK. Targeted RNA sequencing detected a novel fusion gene of <jats:italic>SOX5::ALK<\/jats:italic>. After initial chemotherapy with cyclophosphamide, carboplatin, and etoposide for 2 cycles, the tumor size progressed markedly and the patient underwent a subtotal resection of brain tumor followed by treatment with lorlatinib, an ALK tyrosine kinase inhibitor with central nervous system (CNS) activity. After 3 months of treatment, reduction of tumor size was observed. After 14 months of treatment, partial response was achieved, and the infant had normal growth and development. In conclusion, we identified a case of congenital IHG with a novel <jats:italic>SOX5::ALK<\/jats:italic> fusion that had progressed after chemotherapy and showed partial response and clinical benefit after treatment with the CNS-active ALK inhibitor lorlatinib.<\/jats:p>","DOI":"10.6004\/jnccn.2023.7102","type":"journal-article","created":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T20:29:43Z","timestamp":1708720183000},"source":"Crossref","is-referenced-by-count":14,"title":["An Infant-Type Hemispheric Glioma With SOX5::ALK: A Novel Fusion"],"prefix":"10.6004","volume":"22","author":[{"given":"Chia Chin","family":"Tsai","sequence":"first","affiliation":[{"name":"Department of Pathology, Taipei Medical University Hospital, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man-Hsu","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Pathology, Shuang Ho Hospital, Ministry of Health and Welfare, Taipei Medical University, Zhonghe, New Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Lang","family":"Fang","sequence":"additional","affiliation":[{"name":"Department of Pathology, Taipei Medical University Hospital, Taipei, Taiwan"},{"name":"Department of Pathology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin Li-Chun","family":"Hsieh","sequence":"additional","affiliation":[{"name":"Department of Medical Imaging, Taipei Medical University Hospital, Taipei, Taiwan"},{"name":"Department of Radiology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan"},{"name":"TMU Research Center of Cancer Translational Medicine, Taipei Medical University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsung-Han","family":"Hsieh","sequence":"additional","affiliation":[{"name":"Joint Biobank, Office of Human Research, Taipei Medical University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan-Ling","family":"Ho","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Taipei Medical University Hospital, Taipei, Taiwan"},{"name":"Department of Pediatrics, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan"},{"name":"Taipei Cancer Center, Taipei Medical University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsi","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Taipei Medical University Hospital, Taipei, Taiwan"},{"name":"Department of Pediatrics, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Lan","family":"Tsai","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Taipei Medical University Hospital, Taipei, Taiwan"},{"name":"Department of Pediatrics, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Chien","family":"Kao","sequence":"additional","affiliation":[{"name":"Department of Pathology, Taipei Medical University Hospital, Taipei, Taiwan"},{"name":"Department of Pathology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan"},{"name":"Now with Department of Pathology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James S.","family":"Miser","sequence":"additional","affiliation":[{"name":"Taipei Cancer Center, Taipei Medical University, Taipei, Taiwan"},{"name":"Department of Pediatrics, City of Hope Comprehensive Cancer Center, Duarte, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tai-Tong","family":"Wong","sequence":"additional","affiliation":[{"name":"TMU Research Center of Cancer Translational Medicine, Taipei Medical University, Taipei, Taiwan"},{"name":"Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan"},{"name":"Division of Pediatric Neurosurgery, Department of Neurosurgery, Taipei Medical University Hospital, Taipei, Taiwan"},{"name":"Taipei Neuroscience Institute, Taipei Medical University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Yu","family":"Su","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology\/Oncology, Department of Pediatrics, China Medical University Children\u2019s Hospital, Taichung, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yen-Lin","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Taipei Medical University Hospital, Taipei, Taiwan"},{"name":"Department of Pediatrics, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan"},{"name":"Taipei Cancer Center, Taipei Medical University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"B1","series-title":"Cancer","first-page":"3243","article-title":"Carboplatin-based primary chemotherapy for infants and young children with CNS tumors","volume":"115","author":"Fouladi M","year":"2009","unstructured":"Fouladi M, Gururangan S, Moghrabi A,  Carboplatin-based primary chemotherapy for infants and young children with CNS tumors. Cancer 2009;115:3243\u20133253."},{"key":"B2","series-title":"J Clin Oncol","article-title":"Phase I trial of lorlatinib in patients with ALK-driven refractory or relapsed neuroblastoma: a New Approaches to Neuroblastoma Consortium study","volume":"38","author":"Goldsmith KC","year":"2020","unstructured":"Goldsmith KC, Kayser K, Groshen SG,  Phase I trial of lorlatinib in patients with ALK-driven refractory or relapsed neuroblastoma: a New Approaches to Neuroblastoma Consortium study. J Clin Oncol 2020;38(Suppl):Abstract 10504."},{"key":"B3","series-title":"N Engl J Med","first-page":"761","article-title":"Lorlatinib in a child with ALK- fusion-positive high-grade glioma","volume":"385","author":"Bagchi A","year":"2021","unstructured":"Bagchi A, Orr BA, Campagne O,  Lorlatinib in a child with ALK- fusion-positive high-grade glioma. N Engl J Med 2021;385:761\u2013763."},{"key":"B4","series-title":"Nat Med","first-page":"1092","article-title":"Lorlatinib with or without chemotherapy in ALK-driven refractory\/relapsed neuroblastoma: phase 1 trial results","volume":"29","author":"Goldsmith KC","year":"2023","unstructured":"Goldsmith KC, Park JR, Kayser K,  Lorlatinib with or without chemotherapy in ALK-driven refractory\/relapsed neuroblastoma: phase 1 trial results. Nat Med 2023;29:1092\u20131102."},{"key":"B5","series-title":"WHO Classification of Tumours: Central Nervous System Tumours","first-page":"81","article-title":"Infant-type hemispheric glioma","author":"Jacques TS","year":"2021","unstructured":"Jacques TS, Tabori U, Varlet P,  Infant-type hemispheric glioma. In: WHO Classification of Tumours: Central Nervous System Tumours, 5th ed. IARC; 2021:81\u201383."},{"key":"B6","series-title":"Nat Commun","first-page":"4343","article-title":"Alterations in ALK\/ROS1\/NTRK\/MET drive a group of infantile hemispheric gliomas","volume":"10","author":"Guerreiro Stucklin AS","year":"2019","unstructured":"Guerreiro Stucklin AS, Ryall S, Fukuoka K,  Alterations in ALK\/ROS1\/NTRK\/MET drive a group of infantile hemispheric gliomas. Nat Commun 2019;10:4343."},{"key":"B7","series-title":"Cancer Discov","first-page":"942","article-title":"Infant high-grade gliomas comprise multiple subgroups characterized by novel targetable gene fusions and favorable outcomes","volume":"10","author":"Clarke M","year":"2020","unstructured":"Clarke M, Mackay A, Ismer B,  Infant high-grade gliomas comprise multiple subgroups characterized by novel targetable gene fusions and favorable outcomes. Cancer Discov 2020;10:942\u2013963."},{"key":"B8","series-title":"Clin Cancer Res","first-page":"2651","article-title":"ALK amplification and rearrangements are recurrent targetable events in congenital and adult glioblastoma","volume":"29","author":"Blandin AF","year":"2023","unstructured":"Blandin AF, Giglio R, Graham MS,  ALK amplification and rearrangements are recurrent targetable events in congenital and adult glioblastoma. Clin Cancer Res 2023;29:2651\u20132667."},{"key":"B9","series-title":"Neuro Oncol","article-title":"High-grade glioma in infants and young children is histologically, molecularly, and clinically diverse\u2014results from the SJYC07 trial and institutional experience","author":"Chiang J","unstructured":"Chiang J, Bagchi A, Li X,  High-grade glioma in infants and young children is histologically, molecularly, and clinically diverse\u2014results from the SJYC07 trial and institutional experience. Neuro Oncol. Published online July 28, 2023. doi:10.1093\/neuonc\/noad130"},{"key":"B10","series-title":"Diagnostics (Basel)","first-page":"648","article-title":"Infantile\/Congenital high-grade gliomas: molecular features and therapeutic perspectives","volume":"10","author":"Ceglie G","year":"2020","unstructured":"Ceglie G, Vinci M, Carai A,  Infantile\/Congenital high-grade gliomas: molecular features and therapeutic perspectives. Diagnostics (Basel) 2020;10:648."},{"key":"B11","series-title":"Eur J Cancer","first-page":"2939","article-title":"High-grade glioma in children under 5 years of age: a chemotherapy only approach with the BBSFOP protocol","volume":"42","author":"Dufour C","year":"2006","unstructured":"Dufour C, Grill J, Lellouch-Tubiana A,  High-grade glioma in children under 5 years of age: a chemotherapy only approach with the BBSFOP protocol. Eur J Cancer 2006;42:2939\u20132945."},{"key":"B12","series-title":"Pediatr Blood Cancer","first-page":"888","article-title":"High-grade astrocytoma in very young children","volume":"49","author":"Sanders RP","year":"2007","unstructured":"Sanders RP, Kocak M, Burger PC,  High-grade astrocytoma in very young children. Pediatr Blood Cancer 2007;49:888\u2013893."},{"key":"B13","series-title":"Eur J Cancer","first-page":"120","article-title":"Primary postoperative chemotherapy without radiotherapy for treatment of brain tumours other than ependymoma in children under 3 years: results of the first UKCCSG\/SIOP CNS 9204 trial","volume":"46","author":"Grundy RG","year":"2010","unstructured":"Grundy RG, Wilne SH, Robinson KJ,  Primary postoperative chemotherapy without radiotherapy for treatment of brain tumours other than ependymoma in children under 3 years: results of the first UKCCSG\/SIOP CNS 9204 trial. Eur J Cancer 2010;46:120\u2013133."},{"key":"B14","series-title":"Crit Rev Oncol Hematol","first-page":"48","article-title":"ALK rearrangements: biology, detection and opportunities of therapy in non-small cell lung cancer","volume":"136","author":"Rosas G","year":"2019","unstructured":"Rosas G, Ruiz R, Araujo JM,  ALK rearrangements: biology, detection and opportunities of therapy in non-small cell lung cancer. Crit Rev Oncol Hematol 2019;136:48\u201355."},{"key":"B15","series-title":"Semin Cancer Biol","first-page":"122","article-title":"The role of SOX family members in solid tumours and metastasis","volume":"67","author":"Grimm D","year":"2020","unstructured":"Grimm D, Bauer J, Wise P,  The role of SOX family members in solid tumours and metastasis. Semin Cancer Biol 2020;67:122\u2013153."},{"key":"B16","series-title":"J Neurooncol","first-page":"247","article-title":"Targetable molecular alterations in congenital glioblastoma","volume":"146","author":"Gilani A","year":"2020","unstructured":"Gilani A, Donson A, Davies KD,  Targetable molecular alterations in congenital glioblastoma. J Neurooncol 2020;146:247\u2013252."},{"key":"B17","series-title":"Acta Neuropathol","first-page":"283","article-title":"Activating NTRK2 and ALK receptor tyrosine kinase fusions extend the molecular spectrum of pleomorphic xanthoastrocytomas of early childhood: a diagnostic overlap with infant-type hemispheric glioma","volume":"143","author":"Lucas CG","year":"2022","unstructured":"Lucas CG, Abdullaev Z, Bruggers CS,  Activating NTRK2 and ALK receptor tyrosine kinase fusions extend the molecular spectrum of pleomorphic xanthoastrocytomas of early childhood: a diagnostic overlap with infant-type hemispheric glioma. Acta Neuropathol 2022;143:283\u2013286."},{"key":"B18","series-title":"JCO Precis Oncol","first-page":"e2200255","article-title":"Lorlatinib for the treatment of ALK fusion-positive infant-type hemispheric glioma: a case report","volume":"6","author":"Greenwell AM","year":"2022","unstructured":"Greenwell AM, Baughan S, Altinok D,  Lorlatinib for the treatment of ALK fusion-positive infant-type hemispheric glioma: a case report. JCO Precis Oncol 2022;6:e2200255."},{"key":"B19","series-title":"Front Oncol","first-page":"1123378","article-title":"Case report: ATIC-ALK fusion in infant-type hemispheric glioma and response to lorlatinib","volume":"13","author":"Shahab SW","year":"2023","unstructured":"Shahab SW, Schniederjan M, Vega JV,  Case report: ATIC-ALK fusion in infant-type hemispheric glioma and response to lorlatinib. Front Oncol 2023;13:1123378."},{"key":"B20","series-title":"JCO Precis Oncol","first-page":"e2200547","article-title":"Clinical and molecular evolution of an ALK-driven infant-type hemispheric glioma treated sequentially with second- and third-generation anaplastic lymphoma kinase inhibitors","volume":"7","author":"Gene-Olaciregui N","year":"2023","unstructured":"Gene-Olaciregui N, Perez-Somarriba M, Santa-Mar\u00eda V,  Clinical and molecular evolution of an ALK-driven infant-type hemispheric glioma treated sequentially with second- and third-generation anaplastic lymphoma kinase inhibitors. JCO Precis Oncol 2023;7:e2200547."},{"key":"B21","series-title":"Ann Clin Transl Neurol","first-page":"836","article-title":"Lorlatinib for ALK-fused, infant-type hemispheric glioma with lung metastasis: a case report","volume":"10","author":"Lai M","year":"2023","unstructured":"Lai M, Li S, Li H,  Lorlatinib for ALK-fused, infant-type hemispheric glioma with lung metastasis: a case report. Ann Clin Transl Neurol 2023;10:836\u2013841."},{"key":"B22","series-title":"Jpn J Clin Oncol","first-page":"37","article-title":"Brigatinib and lorlatinib: their effect on ALK inhibitors in NSCLC focusing on resistant mutations and central nervous system metastases","volume":"51","author":"Naito T","year":"2021","unstructured":"Naito T, Shiraishi H, Fujiwara Y. Brigatinib and lorlatinib: their effect on ALK inhibitors in NSCLC focusing on resistant mutations and central nervous system metastases. Jpn J Clin Oncol 2021;51:37\u201344."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/22\/1\/article-e237102.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/22\/1\/article-e237102.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/22\/1\/article-e237102.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T20:29:43Z","timestamp":1708720183000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/22\/1\/article-e237102.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":22,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2023.7102","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2]]}}}